The phase III JBCRG-M06/EMERALD study, whose results accompany this editorial, 16 pursued a head-to-head comparison of eribulin versus taxanes for first-line, HER2-positive locally advanced or MBC. A ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback